|
⚲
|
| Keyboard |
| Redmile Group LLC
✚
|
|
|---|---|
| CRD # | 143606 |
| SEC # | 801-67747 |
| CIK # | 0001425738 |
| AUM | 4,701.1 M (2026-06-30) |
| Employees | 30 (50% Investors, 0% Brokers) |
| Phone | 415-489-9980 |
| Address | 900 Larkspur Landing Circle Larkspur, CA 94939 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Scholar Rock Holding Corp | 0.4 | ||
| Krystal Biotech Inc | 0.2 | ||
| Stoke Therapeutics Inc | 0.1 | ||
| Immunome Inc | 0.1 | ||
| Nurix Therapeutics Inc | 0.1 | ||
| Annexon Inc | 0.1 | ||
| ADC Therapeutics Sa | 0.1 | ||
| RegenxBio Inc | 0.0 | ||
| Shattuck Labs Inc | 0.0 | ||
| Beam Therapeutics Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | RM Special Holdings 9 LLC | 2026-03-01 | 3.5 M | |
| HF | Redmile Strategic Long Only Trading Sub Ltd | [2022-08-15] | 498.6 M | 162.0 M |
| Filed 2026-03-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $286,876 · Net Assets Decline to Disclose | ||||
| HF | Redmile Strategic Trading Sub Ltd | [2022-08-15] | 498.6 M | 169.7 M |
| Filed 2026-03-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $286,876 · Net Assets Decline to Disclose | ||||
| VC | Redmile Growth Investments I LP | [2022-02-09] | 122.0 M | 137.0 M |
| Filed 2022-07-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | RM Special Holdings 8 LLC | 2022-02-09 | 0.4 M | |
| HF | Redco II Master Fund LP | [2021-03-31] | 31.4 M | 1,555.9 M |
| Filed 2021-05-26 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Redmile Biopharma Investments III LP | [2021-02-26] | 500.2 M | 1,133.8 M |
| Filed 2021-01-04 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | RM Special Holdings 4 LLC | 2021-02-26 | ||
| HF | Redco I LP | [2020-08-27] | 187.5 M | 40.6 M |
| Filed 2020-05-26 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Redmile Biopharma Investments II LP | [2019-03-29] | 675.4 M | 661.0 M |
| Offered $675,420,000 · Filed 2020-03-05 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Commission $7,300,000 · Revenue Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 26 | 4.7 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 26 | 4.7 |
| By Discretionary | ||
| Discretionary | 26 | 4.7 |
| Non-Discretionary | 0 | 0.0 |
| Total | 26 | 4.7 |
| By Non-United States Persons | ||
| Non-United States Persons | 3.2 | |
| United States Persons | 1.5 | |
| Total | 26 | 4.7 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Ronan Guilfoyle | Director | 358 | 108 | |
| Roger Hanson | Director | 255 | 86 | |
| Vijayabalan Murugesu | Director | 129 | 26 | |
| Philip Hughes | Director | 87 | 17 | |
| Mike Lee | Executive Officer, Promoter | 21 | 3 | |
| Gerard van Hamel Platerink | Director, Promoter | 19 | 2 | |
| Jeremy Green | Director, Executive Officer, Promoter | 16 | 2 | |
| Amrit Nagpal | Executive Officer, Promoter | 11 | 2 | |
| Redmile Group LLC | Director, Executive Officer, Promoter | 10 | 2 | |
| Rob Faulkner | Promoter | 3 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001425738] | |
| 3 | [0001425738] | |
| 4 | [0001425738] | |
| SC 13D | [0001425738] | |
| SC 13G | [0001425738] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.1B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 5493007T2I6TUUZ37I60 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
ADC Therapeutics SA ADCT
Pre-Funded Warrants · derivative
|
2025-10-27 | Buy | 3,846,153 | $3.90 | 14,999,997 |
|
ADC Therapeutics SA ADCT
Pre-Funded Warrants · derivative
|
2025-10-27 | Buy | 3,846,153 | $3.90 | 14,999,997 |
|
IGM Biosciences Inc IGMS
Non-Voting Common Stock · derivative
|
2025-08-14 | Disposed to issuer | 7,199,325 | ||
|
IGM Biosciences Inc IGMS
Pre-Funded Warrants to Purchase Common Stock · derivative
|
2025-08-14 | Disposed to issuer | 667,666 | ||
|
IGM Biosciences Inc IGMS
Common Stock
|
2025-08-14 | Disposed to issuer | 2,964,843 | ||
|
Shattuck Labs Inc STTK
Stock Option (Right to Buy) · derivative
|
2025-07-14 | Grant | 33,150 | $0.00 | |
|
IGM Biosciences Inc IGMS
Common Stock
|
2025-06-30 | Grant | 828 | $0.00 | |
|
ADC Therapeutics SA ADCT
Pre-Funded Warrants · derivative
|
2025-06-11 | Buy | 15,734,267 | $3.43 | 53,968,536 |
|
ADC Therapeutics SA ADCT
Pre-Funded Warrants · derivative
|
2025-06-11 | Buy | 12,465,234 | $3.43 | 42,755,753 |
|
Fate Therapeutics Inc FATE
Stock Option (Right to Buy) · derivative
|
2025-05-29 | Grant | 55,000 | $0.00 | |
|
IGM Biosciences Inc IGMS
Common Stock
|
2025-03-31 | Grant | 828 | $0.00 | |
|
IGM Biosciences Inc IGMS
Common Stock
|
2024-12-31 | Grant | 1,734 | $0.00 | |
|
Fate Therapeutics Inc FATE
Common Stock
|
2024-12-20 | Other | 1,084,936 | $1.68 | 1,822,692 |
|
Fate Therapeutics Inc FATE
Class A Convertible Preferred Stock · derivative
|
2024-12-20 | Other | 116,261 | $8.40 | 976,592 |
|
Fate Therapeutics Inc FATE
Common Stock
|
2024-12-20 | Buy | 397,964 | $1.68 | 668,580 |
|
Fate Therapeutics Inc FATE
Cash-settled Swaps · derivative
|
2024-12-20 | Other | 56,331 | $1.68 | 94,636 |
|
Fate Therapeutics Inc FATE
Class A Convertible Preferred Stock · derivative
|
2024-12-20 | Other | 116,261 | $8.40 | 976,592 |
|
Fate Therapeutics Inc FATE
Common Stock
|
2024-12-20 | Other | 1,084,936 | $1.68 | 1,822,692 |
|
Fate Therapeutics Inc FATE
Common Stock
|
2024-12-20 | Sell | 341,633 | $1.68 | 573,943 |
|
Fate Therapeutics Inc FATE
Class A Convertible Preferred Stock · derivative
|
2024-12-12 | Conversion | 6,022 | ||
| showing 20 of 200 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Senator Investment Group LP
✚
|
NY | 4,923.6 M |
|
Hill City Capital LP
✚
|
MA | 4,864.0 M |
|
Kinetic Partners Management LP
✚
|
FL | 4,727.8 M |
|
Washington Harbour Partners LP
✚
|
VA | 4,725.1 M |
|
Clearwater Management Co Inc
✚
|
MN | 4,681.9 M |
|
Shelter Growth Capital Partners LLC
✚
|
CT | 4,662.5 M |
|
Caxton Associates USA LLC
✚
|
NY | 4,627.3 M |
|
Corvex Management LP
✚
|
NY | 4,568.4 M |
|
VR Adviser LLC
✚
|
NY | 4,495.4 M |
|
Evanston Capital Management LLC
✚
|
IL | 4,490.6 M |